NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. AXSMa biopharmaceutical company that develops and offers novel therapies for the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat on Thursday at the 22nd annual Needham Virtual Healthcare Conference on April 20, 2023 at 1:30 p.m. Eastern Time.

A live webcast and archive of the event can be viewed on the Webcasts & Presentations page in the Investors section of the Company’s website at www.axsome.com.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for diseases of the central nervous system (CNS) for which treatment options are limited. By developing therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS disorders. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and offer physicians new therapeutic options. For more information, visit the company’s website at axsome.com. The Company may, from time to time, post material, non-public information on the Company’s website.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements.” We may, in some cases, use terms such as “forecast”, “believe”, “potential”, “continue”, “estimate”, “anticipate”, “expect”, “plan”, “intend”, “may”, “could”, “could”, “will”, “should” or other words expressing uncertainty of future events or results to identify these forward-looking statements. In particular, the Company’s statements regarding trends and possible future results are examples of such forward-looking statements. The forward-looking statements involve risks and uncertainties, including but not limited to the continued commercial success of our Sunosi^® and Auvelity^® products and the…